Anti-VEGF Drugs Do Not Differ in RPE Tear Risk for Wet AMD Eyes
A retrospective comparative trial showed that agents including bevacizumab, ranibizumab and aflibercept are linked to similar likelihood of RPE tears.
Higher Psilocybin Dose Benefits Treatment-Resistant Depression at 3 Weeks
New phase 2 data show a synthetic, proprietary 25 mg dose from COMPASS may fare better for adult patients than a 10 mg dose.
Age-Related Macular Degeneration Supplement Formulas Vary from Evidence
An analysis of over-the-counter products show not all AMD-targeting supplements match the recommended dosage from the National Institutes of Health.
Vitiligo Linked to Reduced Risk of COVID-19 Hospitalization, Death
New cohort analysis data suggest the risk of COVID-19 death is about 38% decreased among patients with the autoimmune disease.
Lebrikizumab Maintains Atopic Dermatitis Efficacy Over 1 Year
New phase 3 data shared at Fall Clinical Dermatology show the IL-13 inhibitor maintained skin clearance observed at 16 weeks.
Christopher Bunick, MD, PhD: Following Up on Benzene Exposure Risk
After the announced recall of dry shampoo products by Unilever this month, dermatologists anticipate an uptick in patient concerns.
How To Improve Pediatric Eczema Screening, Prevention
Lawrence Eichenfield, MD, discusses recent achievements in identifying and possibly preventing atopic dermatitis development in infants.
Unilever Dry Shampoo Products Recalled for Benzene Risk
Yale dermatologist Christopher Bunick, MD, PhD, discusses the recurring issue with increased levels of the carcinogen found in self-care and cosmetic products.
How Do We Treat Children with Systemic Eczema Therapies?
With dupilumab already available and JAK inhibitors on the way, clinicians have a bevy of treatments designated for pediatric patients.
The Future of Tailored Alopecia Treatment
In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.
Bimekizumab Provides Sustained Psoriasis Benefit, Tolerability Over 3 Years
New open-label extension data support the long-term use of the systemic therapy in patients with moderate-to-severe disease.
Advances to Alopecia Areata Treatment and Diagnostics
Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.
Dupilumab Improves Pediatric Eczema Symptoms Better than Methotrexate, Cyclosporine
Real-world analysis comparing systemic therapies show dupilumab better improves EASI and quality of life among affected children.
Baricitinib Has Reinvigorated Patients with Alopecia Areata
Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.
Atopic Dermatitis on Head, Face, Neck and Hands Linked to Worsened Quality of Life
Data from the ongoing TARGET-DERM AM observational study show patients with more exposed disease have generally worse severity and challenges linked to quality of life.
FDA Approves Upadacitinib for Active Non-Radiographic Axial Spondyloarthritis
The sixth indication for the JAK inhbitior from AbbVie makes it the first in class approved for both nr-axSpA and ankylosing spondylitis.
Why Ruxolitinib May Alter Atopic Dermatitis Care Options
The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.
How Likely Is A Vaccine for Acne?
Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.
Apremilast May Significantly, Safely Benefit Severe Pediatric Psoriasis
New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in chilren and adolescents.
Rocatinlimab Significantly Improves Atopic Dermatitis Severity Over 36 Weeks
The novel OX40 inhibitor showed significant efficacy in 4 different doses versus placebo in Fall Clinical Dermatology data.
What Does an Acne Patient Want From Clinical Care?
With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.
Guselkumab Safety Similar to Placebo for Psoriasis Patients Over 5 Years
Pooled data from 7 clinical trials show the IL-23 inhibitor is not associated with worsened risk of adverse events or infections.
How Narrow-Spectrum Antibiotics Shifted Acne Treatment Strategy
Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.
What Does It Take to Initiate JAK Inhibitors for Psoriasis?
Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.
The Implications of Deucravacitinib's Approval for Psoriasis
A dermatologist considers what the orally-administered TYK2 inhibitor will provide eligible adult patients.
Risankizumab Consistently Clears Psoriasis Skin Over 5 Years
Data from the phase 3 LIMMitless show patients received long-term benefit from the biologic, regardless of baseline demographic or disease status.
JAK Inhibitors Ended the Novel Atopic Dermatitis Treatment "Drought"
Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.
The Emerging Oral & Topical Agents for Psoriasis
Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.
Insomnia Symptoms Associated with Self-Reported & Objective Cognition Scores
New analyses suggest insomnia symptoms among older patients may play a pivotal role in the relationship between objective and self-reported cognition.
Insomnia Driven by Behavioral, Sleep Modifications, Light Exposure During COVID-19
A cross-sectional analysis from the France COVID-19 lockdown period resulted in a predictive model for insomnia risk.
2 Clarke Drive Cranbury, NJ 08512